Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non–small Cell Lung Cancer PDX Models with Driver Genetic Alterations

Scientists selected five NSCLC patient-derived xenografts (PDXs) with genetic alterations from established PDXs and the corresponding molecular targeted therapy was administered orally for 21 consecutive days.